JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB98596

Goat F(ab')2 Anti-Human IgG - Fc (PE), pre-adsorbed

4

(1 Review)

|

(15 Publications)

Goat F(ab')2 Anti-Human IgG - Fc (PE) is a pre-adsorbed secondary antibody with a maximum absorption wavelength of 480;565nm and a maximum emission wavelength of 578nm. Suitable for Flow Cytometry.

- Preadsorbed to prevent cross-reactivity and reduce background staining
- F(ab) fragment secondary antibodies eliminate non-specific binding between Fc regions of antibodies and Fc receptors on immune cells
- Cited in over 10 publications

View Alternative Names

Immunoglobulin heavy constant gamma 1, Ig gamma-1 chain C region, Ig gamma-1 chain C region EU, Ig gamma-1 chain C region KOL, Ig gamma-1 chain C region NIE, IGHG1

1 Images
Flow Cytometry - Goat F(ab')2 Anti-Human IgG - Fc (PE), pre-adsorbed (AB98596)
  • Flow Cyt

Unknown

Flow Cytometry - Goat F(ab')2 Anti-Human IgG - Fc (PE), pre-adsorbed (AB98596)

Flow Cytometry - Goat F(ab')2 Anti-Human IgG - Fc (PE), pre-adsorbed (ab98596)

CHO cell line expressing membrane bound human TNFα (stable transfectants) was incubated with 10 μg/ml Remicade (anti-human TNFa monoclonal antibody) for 1 h in 4°C. The unbound antibody was washed off by centrifugation (300x g for 5 min) and binding of remicade was detected with PE Goat F(ab)2 anti-hIgG Fc (ab98596) – 1 : 100 (5 μg/ml), 30 min incubation in 4°C. The cells were washed twice in FACS buffer (2.5% BSA, 0.1% sodium azide in dPBS), before flow cytometric analysis.

PE goat F(ab)2 anti-hIgG detected binding of remicade to TNFα CHO cell line giving strong positive signal, however there was some non-specific binding to the cells alone. Further optimisation of the reagent concentration and washing procedure should improve the background signal.

Key facts

Host species

Goat

Target species

Human

Target isotype

IgG

Target specificity

Fc region

Minimal cross-reactivity

Mouse, Rat,

Pre-adsorbed

Yes

Conjugation

PE

Excitation/Emission

Ex: 480;565nm, Em: 578nm

Applications

Flow Cyt

applications

Clonality

Polyclonal

Isotype

IgG

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Flow Cyt": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/50 - 1/200", "notes":"<p></p>" } } }

Product details

By immunoelectrophoresis and ELISA this antibody reacts specifically with human IgG. Cross reactivity with IgA and IgM is negligible. No antibody was detected against non-immunoglobulin serum proteins. Less than 1% cross reactivity to mouse and rat IgG was detected. This antibody may cross react with IgG from other species.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Purification notes
This antibody was isolated by affinity chromatography using antigen coupled to agarose beads. F(ab')2 fragment were generated using a pepsin digestion. Fc fragments and whole IgG molecules have been removed. Fragments were conjugated to Phycoerythrin.
Storage buffer
pH: 6.8 - 7.4 Preservative: 0.09% Sodium azide Constituents: PBS, 0.2% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C

Product protocols

Target data

Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed : 20176268, PubMed : 22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed : 17576170, PubMed : 20176268). Mediates IgG effector functions on monocytes triggering ADCC of virus-infected cells.
See full target information IGHG1

Additional targets

IGHG3,IGHG2,IGHG4

Publications (15)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in immunology 15:1439418 PubMed39267766

2024

The adjuvant BcfA activates antigen presenting cells through TLR4 and supports T and T1 while attenuating T2 gene programming.

Applications

Unspecified application

Species

Unspecified reactive species

Mohamed M Shamseldin,Kaitlin A Read,Jesse M Hall,Jasmine A Tuazon,Jessica M Brown,Myra Guo,Yash A Gupta,Rajendar Deora,Kenneth J Oestreich,Purnima Dubey

Cancer research 84:1680-1698 PubMed38501978

2024

ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation.

Applications

Unspecified application

Species

Unspecified reactive species

Hui Yuwen,Huajing Wang,Tengteng Li,Yijing Ren,Yun-Kai Zhang,Peng Chen,Ao Sun,Gang Bian,Bohua Li,David Flowers,Marc Presler,Kalyanasundaram Subramanian,Jia Xue,Jingjing Wang,Kevin Lynch,Jay Mei,Xiaowen He,Bo Shan,Bing Hou

eLife 12: PubMed37737226

2023

PerTurboID, a targeted in situ method reveals the impact of kinase deletion on its local protein environment in the cytoadhesion complex of malaria-causing parasites.

Applications

Unspecified application

Species

Unspecified reactive species

Heledd Davies,Hugo Belda,Malgorzata Broncel,Jill Dalimot,Moritz Treeck

Phytomedicine : international journal of phytotherapy and phytopharmacology 118:154942 PubMed37421767

2023

Kaempferol inhibits SARS-CoV-2 invasion by impairing heptad repeats-mediated viral fusion.

Applications

Unspecified application

Species

Unspecified reactive species

Junwei Gao,Can Cao,Mingfei Shi,Shihao Hong,Shijie Guo,Jing Li,Tengxiao Liang,Ping Song,Ruodan Xu,Ning Li

Journal for immunotherapy of cancer 10: PubMed35728874

2022

Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells.

Applications

Unspecified application

Species

Unspecified reactive species

Yi-Chiu Kuo,Cheng-Fu Kuo,Kurt Jenkins,Alfur Fu-Hsin Hung,Wen-Chung Chang,Miso Park,Brenda Aguilar,Renate Starr,Jonathan Hibbard,Christine Brown,John C Williams

iScience 25:103720 PubMed35005526

2022

ACE2 can act as the secondary receptor in the FcγR-dependent ADE of SARS-CoV-2 infection.

Applications

Unspecified application

Species

Unspecified reactive species

Zai Wang,Tingting Deng,Yulian Zhang,Wenquan Niu,Qiangqiang Nie,Shengnan Yang,Peipei Liu,Pengfei Pei,Long Chen,Haibo Li,Bin Cao

Cell reports 35:109142 PubMed34010642

2021

Inhibitory affinity modulation of FcγRIIA ligand binding by glycosphingolipids by inside-out signaling.

Applications

Unspecified application

Species

Unspecified reactive species

Koshu Okubo,Michael D Brenner,Xavier Cullere,Gurpanna Saggu,Myra L Patchen,Nandita Bose,Saki Mihori,Zhou Yuan,Clifford A Lowell,Cheng Zhu,Tanya N Mayadas

Nature communications 11:5597 PubMed33154358

2020

A universal dual mechanism immunotherapy for the treatment of influenza virus infections.

Applications

Unspecified application

Species

Unspecified reactive species

Xin Liu,Boning Zhang,Yingcai Wang,Hanan S Haymour,Fenghua Zhang,Le-Cun Xu,Madduri Srinivasarao,Philip S Low

Cell reports 32:107918 PubMed32668215

2020

Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.

Applications

Unspecified application

Species

Unspecified reactive species

Jinkai Wan,Shenghui Xing,Longfei Ding,Yongheng Wang,Chenjian Gu,Yanling Wu,Bowen Rong,Cheng Li,Siqing Wang,Kun Chen,Chenxi He,Dandan Zhu,Songhua Yuan,Chengli Qiu,Chen Zhao,Lei Nie,Zhangzhao Gao,Jingyu Jiao,Xiaoyan Zhang,Xiangxi Wang,Tianlei Ying,Haibin Wang,Youhua Xie,Yanan Lu,Jianqing Xu,Fei Lan

Cancer cell 37:850-866.e7 PubMed32442402

2020

Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaojie Yu,H T Claude Chan,Hayden Fisher,Christine A Penfold,Jinny Kim,Tatyana Inzhelevskaya,C Ian Mockridge,Ruth R French,Patrick J Duriez,Leon R Douglas,Vikki English,J Sjef Verbeek,Ann L White,Ivo Tews,Martin J Glennie,Mark S Cragg
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com